TriangleNCT00177047 · OUTCOME
Time to Relapse
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Days
- Interval / dispersion
- Standard Deviation
- Time frame
- 1 year
What was measured
Mean number of days among patients relapsing
Groups in this outcome
Chemotherapy and Transplant Treatment
Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\^2). Post-transplant maintenance therapy is then prescribed if appropriate.
| Group | Source count |
|---|---|
| Chemotherapy and Transplant Treatment | 69 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Chemotherapy and Transplant Treatment | 182.9 | 113.5 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 113.5
- value
- 182.9
- denoms
- counts
- group Id
- OG000
- value
- 69
- units
- Participants
- description
- Mean number of days among patients relapsing
- dispersion Type
- Standard Deviation
- groups
- description
- Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\^2). Post-transplant maintenance therapy is then prescribed if appropriate.
- id
- OG000
- title
- Chemotherapy and Transplant Treatment
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Time to Relapse
- type
- SECONDARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice